Legend Biotech (LEGN) Total Current Liabilities (2019 - 2025)
Legend Biotech (LEGN) posted Total Current Liabilities of $636.4 million for Q4 2025, up 46.78% on a QoQ basis from $433.6 million in Q3 2025, and up 129.17% year-over-year from $277.7 million in Q4 2024.
Legend Biotech (LEGN) has 7 years of Total Current Liabilities data on file, last reported at $636.4 million in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 129.17% year-over-year to $636.4 million; the TTM figure through Dec 2025 stood at $636.4 million (up 129.17% YoY), while the FY2025 annual figure was $636.4 million, up 129.17% from the prior year.
- Total Current Liabilities advanced to $636.4 million in Q4 2025, from $433.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $636.4 million in Q4 2025 and bottomed at $145942.0 in Q1 2021.
- A 5-year average of $265.7 million and a median of $255.4 million in 2021 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 226883.16% — and 2023, when it fell 27.32%.
- Year by year, Total Current Liabilities stood at $229.2 million in 2021, then increased by 29.92% to $297.8 million in 2022, then declined by 27.32% to $216.4 million in 2023, then rose by 28.32% to $277.7 million in 2024, then jumped by 129.17% to $636.4 million in 2025.
- The last three Total Current Liabilities figures came in at $636.4 million (Q4 2025), $433.6 million (Q3 2025), and $265.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 289.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 636.40 Mn |
| Sep 30, 2025 | 433.57 Mn |
| Jun 30, 2025 | 265.48 Mn |
| Mar 31, 2025 | 234.37 Mn |
| Dec 31, 2024 | 277.70 Mn |
| Sep 30, 2024 | 270.89 Mn |
| Jun 30, 2024 | 294.30 Mn |
| Mar 31, 2024 | 249.68 Mn |
| Dec 31, 2023 | 216.42 Mn |
| Sep 30, 2023 | 175.22 Mn |
| Jun 30, 2023 | 201.38 Mn |
| Mar 31, 2023 | 238.18 Mn |
| Dec 31, 2022 | 297.79 Mn |
| Mar 31, 2022 | 225.53 Mn |
| Dec 31, 2021 | 229.20 Mn |
| Sep 30, 2021 | 275.37 Mn |
| Jun 30, 2021 | 261.10 Mn |
| Mar 31, 2021 | 145,942.00 |
| Dec 31, 2020 | 115.57 Mn |
| Sep 30, 2020 | 123,522.00 |
| Jun 30, 2020 | 115,031.00 |
| Dec 31, 2019 | 127.76 Mn |